|
| 36004816 | Natriuretic peptide pathways in heart failure: further therapeutic possibilities. | Cardiovasc Res | 2023 |
| 37417873 | Sex-based differences in metabolic protection by the ANP genetic variant rs5068 in the general population. | Am J Physiol Heart Circ Physiol | 2023 |
| 37239899 | Evidence for Angiotensin II as a Naturally Existing Suppressor for the Guanylyl Cyclase A Receptor and Cyclic GMP Generation. | Int J Mol Sci | 2023 |
| 36747784 | EVIDENCE FOR ANGIOTENSIN II AS A NATURALLY EXISTING SUPPRESSOR FOR THE NATRIURETIC PEPTIDE SYSTEM. | bioRxiv | 2023 |
| 34270705 | Cyclic GMP modulating drugs in cardiovascular diseases: mechanism-based network pharmacology. | Cardiovasc Res | 2022 |
| 35674049 | MANP Activation Of The cGMP Inhibits Aldosterone Via PDE2 And CYP11B2 In H295R Cells And In Mice. | Hypertension | 2022 |
| 35573050 | Pre-clinical data supporting immunotherapy for HIV using CMV-HIV-specific CAR TÂ cells with CMV vaccine. | Mol Ther Methods Clin Dev | 2022 |
| 35821229 | Purification, characterization, and preliminary serial crystallography diffraction advances structure determination of full-length human particulate guanylyl cyclase A receptor. | Sci Rep | 2022 |
| 35656806 | Proteomic Biomarkers of Sacubitril/Valsartan Treatment Response in Heart Failure With Preserved Ejection Fraction: Molecular Insights Into Sex Differences. | Circ Heart Fail | 2022 |
| 35045724 | MANP (M-Atrial Natriuretic Peptide) Reduces Blood Pressure and Furosemide-Induced Increase in Aldosterone in Hypertension. | Hypertension | 2022 |
| 35222065 | Natriuretic Peptides and Blood Pressure Homeostasis: Implications for MANP, a Novel Guanylyl Cyclase a Receptor Activator for Hypertension. | Front Physiol | 2022 |
| 35001638 | Cardiorenal Effects of Long-Term Phosphodiesterase V Inhibition in Pre-Heart Failure. | J Am Heart Assoc | 2022 |
| 35229006 | CRISPR-Cas9-mediated gene disruption of HIV-1 co-receptors confers broad resistance to infection in human T cells and humanized mice. | Mol Ther Methods Clin Dev | 2022 |
| 34818071 | Novel Humanized Peripheral Blood Mononuclear Cell Mouse Model with Delayed Onset of Graft-versus-Host Disease for Preclinical HIV Research. | J Virol | 2022 |
| 32747497 | B-type natriuretic peptide and cardiac remodelling after myocardial infarction: a randomised trial. | Heart | 2021 |
| 34930837 | Discovery of small molecule guanylyl cyclase A receptor positive allosteric modulators. | Proc Natl Acad Sci U S A | 2021 |
| 34529829 | THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: Catalytic receptors. | Br J Pharmacol | 2021 |
| 34405565 | Effects of phosphodiesterase V inhibition alone and in combination with BNP on cardiovascular and renal response to volume load in human preclinical diastolic dysfunction. | Physiol Rep | 2021 |
| 34545097 | Exosome-mediated stable epigenetic repression of HIV-1. | Nat Commun | 2021 |
| 34838159 | Identification of a therapeutic interfering particle-A single-dose SARS-CoV-2 antiviral intervention with a high barrier to resistance. | Cell | 2021 |
| 34657445 | First-in-Human Study of MANP: A Novel ANP (Atrial Natriuretic Peptide) Analog in Human Hypertension. | Hypertension | 2021 |
| 34222720 | STOP-HF Trial: Higher Endogenous BNP and Cardiovascular Protection in Subjects at Risk for Heart Failure. | JACC Basic Transl Sci | 2021 |
| 34246604 | Prognostic Value of Urinary and Plasma C-Type Natriuretic Peptide in Acute Decompensated Heart Failure. | JACC Heart Fail | 2021 |
| 34039742 | CRED9: A differentially expressed elncRNA regulates expression of transcription factor CEBPA. | RNA | 2021 |
| 33997628 | Renal Outcomes in Patients with Systolic Heart Failure Treated With Sacubitril-Valsartan or Angiotensin Converting Enzyme Inhibitor/Angiotensin Receptor Blocker. | Mayo Clin Proc Innov Qual Outcomes | 2021 |
| 33461312 | Angiotensin (1-12) in Humans With Normal Blood Pressure and Primary Hypertension. | Hypertension | 2021 |
| 33189632 | Atrial Natriuretic Peptide and Treatment With Sacubitril/Valsartan in Heart Failure With Reduced Ejection Fraction. | JACC Heart Fail | 2021 |
| 30907411 | C-type natriuretic peptide: the heart's guardian angel. | Eur Heart J | 2020 |
| 32022596 | Long-term blood pressure lowering and cGMP-activating actions of the novel ANP analog MANP. | Am J Physiol Regul Integr Comp Physiol | 2020 |
| 32105984 | Rationale and design for a multicenter, randomized, double-blind, placebo-controlled, phase 2 study evaluating the safety and efficacy of the soluble guanylate cyclase stimulator praliciguat over 12 weeks in patients with heart failure with preserved ejection fraction (CAPACITY HFpEF). | Am Heart J | 2020 |
| 33079154 | Effect of Praliciguat on Peak Rate of Oxygen Consumption in Patients With Heart Failure With Preserved Ejection Fraction: The CAPACITY HFpEF Randomized Clinical Trial. | JAMA | 2020 |
| 32760917 | Neprilysin in HFrEF: Differential Regulation of Tissue Versus Circulating Neprilysin. | JACC Basic Transl Sci | 2020 |
| 32611204 | Natriuretic Peptides, Inflammation, and Sounding the Alarm. | Circ Heart Fail | 2020 |
| 32171762 | Natriuretic Peptides as Inclusion Criteria in Clinical Trials: A JACC: Heart Failure Position Paper. | JACC Heart Fail | 2020 |
| 32402167 | Vericiguat - Another Victory for Targeting Cyclic GMP in Heart Failure. | N Engl J Med | 2020 |
| 31392960 | Circulating Neprilysin in Patients With Heart Failure and Preserved Ejection Fraction. | JACC Heart Fail | 2020 |
| 30508635 | High doses of ANP and BNP exacerbate lipolysis in humans and the lipolytic effect of BNP is associated with cardiac triglyceride content in pigs. | Peptides | 2019 |
| 31909303 | Cardiac Versus Renal Response to Volume Expansion in Preclinical Systolic Dysfunction With PDEV Inhibition and BNP. | JACC Basic Transl Sci | 2019 |
| 31844088 | Association Between Cardiac Natriuretic Peptides and Lipid Profile: a Systematic Review and Meta-Analysis. | Sci Rep | 2019 |
| 31784477 | Correction: Discovery of <i>O</i>-glycans on atrial natriuretic peptide (ANP) that affect both its proteolytic degradation and potency at its cognate receptor. | J Biol Chem | 2019 |
| 31713546 | The Kidney, Bone Marrow, and Heart Connection in Acute Kidney Injury: Role of Galecin-3. | JACC Basic Transl Sci | 2019 |
| 29941213 | Natriuretic peptide based therapeutics for heart failure: Cenderitide: A novel first-in-class designer natriuretic peptide. | Int J Cardiol | 2019 |
| 31186350 | Discovery of <i>O</i>-glycans on atrial natriuretic peptide (ANP) that affect both its proteolytic degradation and potency at its cognate receptor. | J Biol Chem | 2019 |
| 31269783 | Atrial Natriuretic Peptide: A Molecular Target of Novel Therapeutic Approaches to Cardio-Metabolic Disease. | Int J Mol Sci | 2019 |
| 31582140 | Myocardial Aging, the Cardiac Atria, and BNP: What Does it All Mean? | J Am Coll Cardiol | 2019 |
| 31521687 | Differential Regulation of ANP and BNP in Acute Decompensated Heart Failure: Deficiency of ANP. | JACC Heart Fail | 2019 |
| 31345101 | Soluble Neprilysin in the General Population: Clinical Determinants and Its Relationship to Cardiovascular Disease. | J Am Heart Assoc | 2019 |
| 31537750 | Novel Therapeutic Approaches Targeting the Renin-Angiotensin System and Associated Peptides in Hypertension and Heart Failure. | Pharmacol Rev | 2019 |
| 31362934 | Atrial Natriuretic Peptide, Heart Failure and the Heart as an Endocrine Organ. | Clin Chem | 2019 |
| 30954448 | C53: A novel particulate guanylyl cyclase B receptor activator that has sustained activity in vivo with anti-fibrotic actions in human cardiac and renal fibroblasts. | J Mol Cell Cardiol | 2019 |